Erythropoietin-derived peptide and use therefor

Abstract

Provided are a peptide which has an amino acid sequence in the first sequence in a sequence list and is effective in preventing cell damage, and a pharmaceutical composition for preventing cell damage, the pharmaceutical composition including the peptide as an active ingredient. The peptide according to the present invention not only exhibits substantially better biological activities than conventional natural human erythropoietin in terms of various cell protection activities, but also has a substantially simpler structure than the natural human erythropoietin. Thus, the peptide may easily pass through a tissue-blood barrier and is economically advantageous due to its low production cost. Accordingly, the pharmaceutical composition including the peptide according to the present invention as an active component is effective for the prevention and treatment of stroke, mechanical damage or ischemic injury to the nervous system, myocardial infarction, diabetes, heart failure, peripheral vascular disorders, diabetic retinopathy, diabetic nephritis, diabetic neuropathy, glaucoma, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Lou Gehrig's disease, and acute and chronic renal dysfunction.

Description

technical field [0001] The present invention relates to erythropoietin-derived peptides and pharmaceutical compositions containing the peptides. Background technique [0002] During survival, the human body is exposed to a constant stream of stimuli and noxious elements, internal or external, against which the individual protects his body through various mechanisms. Such harmful factors include various factors such as mechanochemical risk factors, hypoxia, infection, etc. In order to protect the body from these harmful factors, various mechanisms for defending against harmful factors have been found in individuals, even as small as cell units . Various cytokines (cell factors) secreted through this mechanism not only defend against initial external harmful factors, but also defend against chemical and immunological damage caused by secondary internal harmful substances produced by cells that have completed the defense mechanism and ended their lifespan , so as to prevent c...

AI Technical Summary

Problems solved by technology

Thus, it is known that although EPO is a protein with very high activity, its production cost is very high; when EPO is administered from peripheral blood vessels, it cannot be transported due to the tissue-blood barrier (tissue-blood barrier) existing in some target organs, etc. To the target organ, so there is difficulty in drug delivery (Non-Patent Documents 10-12)

Images